An open-label, ascending-dose, clinical trial of intra-arterial microplasmin administration in patients with acute peripheral arterial occlusion

Trial Profile

An open-label, ascending-dose, clinical trial of intra-arterial microplasmin administration in patients with acute peripheral arterial occlusion

Discontinued
Phase of Trial: Phase II

Latest Information Update: 03 Jun 2014

At a glance

  • Drugs Ocriplasmin (Primary)
  • Indications Arterial occlusive disorders
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors ThromboGenics
  • Most Recent Events

    • 17 Nov 2008 Actual patient number (19) added as reported by ClinicalTrials.gov.
    • 23 Oct 2008 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 19 Apr 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top